TRVN:OTCMKTS
Trevena Inc
0,012Â USD
0,00%
(0,00) 1G
6 ott, 10:01:51 GMT-4 · USD
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per TRVN in corso…
Cap. mercato
10,37K
Vol. medio
182,00
Volume
2,00
Max 52 sett.
1,50Â USD
Min 52 sett.
0,00Â USD
Beta
1,07
Azioni in circolazione
864,00K
N. di dipendenti
23
Cap. mercato
10,37K
Vol. medio
182,00
Volume
2,00
Max 52 sett.
1,50Â USD
Min 52 sett.
0,00Â USD
Beta
1,07
Azioni in circolazione
864,00K
N. di dipendenti
23
Articoli giornalistici
Da fonti web e partner giornalistici
Giocare in Borsa Online
·
1 giorno fa
Dell batte l’S&P 500: ritorno annuo al 65% in cinque anni
www.giocareinborsa.com
·
2 ore fa
Wall Street aspetta ASML e Taiwan Semi: S&P 500 vicino ai massimi
Investire.biz
·
2 ore fa
Utili S&P 500 nel terzo trimestre: FactSet stima un +30%
Profilo
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Informazioni su Trevena Inc